Study: IV Iron Use Less with Once-Monthly ESA
Once-monthly injections of peginesatide are as effective as one to three injections per week of epoetin in maintaining hemoglobin levels.
Once-monthly injections of peginesatide are as effective as one to three injections per week of epoetin in maintaining hemoglobin levels.
A German study found that living kidney donation is safe and most donors report that they would donate again.
Obstructive uropathy is rarely found to be a cause of acute kidney injury.
They may differ from hemodialysis patients with respect to case mix, volume status, disease management, and routine exposure to anticoagulation.
Tolvaptan slows kidney growth and renal decline.
New findings underscore the need for continued improvement in the recognition and management of patients with AKI.
An investigational drug that in early clinical studies looked like it could slow progression of CKD has been shown in two phase 3 clinical trials that it is no better than placebo.
Nearly 11% of hemodialysis (HD) patients who discontinued use of a phosphate binder did so because of side effects.
Some higher-intensity statin formulations are associated with an increased risk of acute kidney injury (AKI).
Renal transplant recipients who use of PPIs and MMF in the first year after transplantation may be at increased risk for allograft acute rejection.